Abstract The idea that somatic ERa mutations could play an important role in the evolution of hormonedependent breast cancers was proposed some years ago (Fuqua J Mammary Gland Biol Neoplasia 6(4): 407-417, 2001; Dasgupta et al. Annu Rev Med 65:279-292, 2013), but has remained controversial until recently. A significant amount of new data has confirmed these initial observations and shown their significance, along with much additional work relevant to the treatment of breast cancer. Thus, it is the purpose of this review to summarize the research to date on the existence and clinical consequences of ERa mutations in primary and metastatic breast cancer.
Introduction
We will revisit the hypothesis put forth about the role of ERa mutations in breast cancer [1] , and scrutinize recent data along with their clinical implications. It was hypothesized that maintenance of ERa expression, along with the selection of specific ERa mutations, was key events in breast cancer progression, most probably due to the selective pressure of hormonal treatment (Fig. 1 , reprinted from [1] ), and current research is moving quickly in support of this original hypothesis. The majority of breast cancers express ERa, where it functions as a ligand-dependent transcription factor driving tumor growth and survival. We know that in the absence of hormone, histone deacetylase and receptor co-repressors are bound to the receptor, and silence transcription. When hormone binds to the receptor, the activated receptor complex displaces repressor proteins and acetyltransferases are recruited to the complex, along with co-activator proteins such as the p160 co-activator (SRC1-3) complex, thereby initiating transcription [2] . Thus ER's ligand dependence can be viewed as Nature's ''brake'' on the receptor-''no gas, no go.'' All endocrine therapies in breast cancer target the ER signaling pathway, either by directly antagonizing ERa, with (e.g., fulvestrant; Faslodex TM ) or without (tamoxifen [Tam] ; Nolvadex TM ) enhancing its degradation, or by strategies that deprive the receptor of estrogen (aromatase inhibitors [AIs] ). However, these treatments generate different cellular stresses, like the generation of reactive oxygen species with Tam treatment, and the creation of an estrogen deprived but estrogen-hypersensitive environment with AI treatment [3, 4] . These stresses could affect residual circulating tumor cells, occult metastatic tumor deposits, and ERa itself. Thus, different mechanisms evolve to evade these hormonal treatments [3, 5, 6] . We know that adjuvant endocrine therapy can halve the recurrence rate of patients with ER-positive breast cancer, but that late recurrences continue to occur many years after initial diagnosis. The majority of metastatic recurrences arising in ER-positive patients also retain ERa expression, signifying a selection process where maintenance of ERa expression must be important for tumor progression. Approximately, 30-40 % of patients with ER-positive metastatic disease will also respond to first-line hormonal therapies, and another 20 % will experience disease stabilization, thus responses to hormonal therapy can last for many years in some patients with ER-positive breast cancer. Unfortunately, the median survival of patients with metastatic breast cancer is still only 2-3 years [7, 8] with very few patients surviving 20 years after diagnosis of metastases [9] . We need to improve these outcomes, especially in metastatic disease, and we urgently need to block the emergence of late recurrences after adjuvant endocrine therapy.
Breast tumor heterogeneity and evolution
Recent comprehensive genomic studies demonstrated the extreme genetic heterogeneity of primary breast tumors, with the vast majority of mutations occurring at very low frequencies [10] . Notable exceptions were the frequent mutation of the p53 tumor suppressor gene in basal ER-negative tumors, and PIK3CA mutations in luminal ER-positive primary tumors. A study comparing patient-derived xenografts from a patient with a basal breast cancer suggested that primary tumors can undergo genomic evolution, and that minor subpopulations with metastatic potential pre-exist and can emerge during the metastatic process [11] . Deep genomic sequencing of breast tumors has afforded an even clearer picture of the life history of breast tumors, identifying both gene drivers and frequent subclonal expansions during tumor progression [12] . Single cell sequencing has recently confirmed that primary tumors are composed of subclonal populations, where single cell clonal expansion can often seed metastasis [13] . The implication of this pioneering work is that metastases can occur late during tumor development from an advanced primary tumor expansion. Important remaining questions are how does treatment affect this process, and can we target those genes which confer a selective metastatic growth advantage? Answers may lie in the evolution of ERa mutations in some patients which confer relative resistance to hormonal therapy.
Resistance due to mutation of the clinical target
Precision in targeted therapy involves first the identification of key pathways which drive a patient's tumor growth, not only the complete blockade of these pathways, but also anticipation of escape pathways (e.g., resistance mechanisms) so that they can also be blocked therapeutically. Thus, combination hormonal and biologic therapy approaches are required for optimal targeted therapy of ER-positive patients. This strategy was proven feasible with the successful use of the mTOR signaling pathway inhibitor everolimus, combined with a steroidal AI, in breast cancer patients with advanced ERpositive breast cancer previously treated with nonsteroidal AIs [14] . Also, patients with HER2-positive tumors may not always require chemotherapy, but instead more complete blockade of HER receptor family members which dimerize with HER2, plus combined blockade of ERa will be an effective and rational combination strategy [15] .
Mutation of the clinical target is a common resistance mechanism in tumors. For instance, during the past few years, a genetically defined reclassification of nonsmall cell lung cancer (NSCLC) has emerged depending on the specific mutations present. Although not very common in frequency, two subsets are defined by EGFR or ALK activating mutations which confer high sensitivity and durable responses to tyrosine kinase inhibitors [16] . Another subset of NSCLC patients contains BRAF mutations which provide mechanisms of resistance to therapy [17] . Thus, tumor-specific mutations may act in at least two ways. In certain genes, activating mutations might confer enhanced sensitivity, perhaps through ''addiction'' to a specific growth or survival pathway [18] . Alternatively, mutations can confer resistance to targeted therapy, for instance, the specific BRAF mutations in NSCLC described above. Similarly, mutations in PI3 KCA in ER-positive breast cancer have been reported to be associated with better responses to tamoxifen monotherapy [19] , but predict poor response to other targeted therapies such as dual-HER2-targeted therapy [15, 20] . Although infrequent, mutations in the HER2 oncogene are also now being reported in breast tumors [21] , and studies exploring their role in resistance to HER2-targeted therapies are underway.
Thus, it is a surprising fact that the presence of ERa mutations in breast tumors has been largely overlooked during the genomic reclassification of breast tumors in the past decade. Mutation of the clinical target, in this case ERa, is finally an emerging and accepted certainty, as will be detailed below. It is unfortunate that the paucity of reports of ERa mutations in tumors led many to assume that they were not there, an assumption that was based on the analysis of relatively few breast tumor samples with standard, less-sensitive sequencing technologies [22] .
The hypersensitive K303R ERa mutation-an actionable target
ERa is modified by many post-translational modifications (PTMs), such as phosphorylation, sumoylation, acetylation, methylation, and ubiquitination [23] . ERa PTMs can affect its transcriptional activity, its protein turnover, co-activator and co-repressor binding, and response to hormone-mediated cellular signaling [24, 25] . A lysine 303 to arginine (K303R) somatic ERa mutation was reported in 2000, occurring in a third of premalignant breast hyperplasias, and one half of invasive breast tumors [26] . This mutation resides at the boundary between the so-called ''hinge region'' of the receptor and its hormone-binding domain. The hinge region contains sites for many regulatory controls, such as binding of co-activators and co-repressors, and PTMs. The presence of the K303R ERa mutation was controversial for a number of years with several laboratories failing to detect the mutation in invasive tumors using dyelabeled terminator core sequencing. However, Conway et al. [27] subsequently reported in 2005 that the mutation was indeed present in primary breast tumors in a populationbased study using an alternative screening strategy, though the frequency of detection with their method was low (5.7 %). Of course, in hindsight with the overall low gene mutation frequency in primary tumors reported by The Cancer Genome Atlas (TCGA) group of investigators, even this lower frequency of detection was significant because most breast cancer mutations are reported to occur in less than 1-5 % of cases [10, 28] . In 2007, the detection controversy was resolved, showing that the failure to detect the K303R ERa mutation via dye-labeled terminator sequencing was due to the specific 3 and 4-base pair combinations preceding the mutation in both the forward and reverse strands [29] . It has been shown that specific base combinations can affect base pair height reads at the 3 0 base. For instance, the 3-bp combination GAA results in a reduced peak height for the 3 0 base; thus, automated base calling will only detect wild-type sequence at this base, and this 3-base combination is the same sequence combination in the K303R ERa mutation [29] . The K303R ERa mutation can be reliably detected with methods such as SnapShot TM , which uses primer extension sequencing across the mutation site (Fig. 2) . Similarly, Dr. Conway's group showed that methods such as single strand conformation polymorphism (SSCP), which relies on base composition and size for electrophoretic separation of mutant alleles, was effective at resolving the presence of the mutation in invasive tumors [30] . SSCP technology was also used back in 1996 to detect variant RNA splice forms of the receptor [31] , which now are being detected with RNA sequencing (RNA Seq) technologies. The inability of high-throughput sequencing methods, such as the Illumina TM sequencing technology, to detect the K303R ERa mutation is thus consistent with its not being reported within the large, publically available TCGA database of primary breast tumors. Undoubtedly, there are a small percentage of tumor-specific mutations which are not resolved with next generation sequencing.
There is much known about the molecular mechanisms of altered activities associated with the K303R ERa mutation, and the clinical implications of these alterations. These studies show that ERa mutations are actionable clinical targets. The K303R ERa mutation alters response to the antiestrogen Tam, but only in a cellular background with elevated cellular growth factor stimulation which converts Tam into an agonist in vitro in mutation-expressing cells. The lysine to arginine mutation creates a new AKT phosphorylation site at ERa serine (S) 305 [32] , which is an important phosphorylation site in modulating ER's response to Tam [33] . The mutation enhances constitutive phosphorylation at the S305 site as well, which has been shown to be important for several aspects of antiestrogen action [32] . The mutation blocks acetylation sites within this region preventing this PTM [34] that then affects other downstream PTM events, such as methylation, thereby stabilizing the receptor [35] . The K303R ERa mutation also exhibits increased binding with members of the SRC coactivator family (SRC-1 and 2), and decreased binding to receptor co-repressors, such as NCOR1 and BRCA1, leading to increased promoter occupancy [26, 36, 37] , which then enhances ligand-independent activity of the receptor. This ligand-independent activity could provide a selective growth advantage, especially in postmenopausal women with breast cancer where circulating levels of estrogen are low, but still capable of stimulating the growth of mutant-expressing cells. As a consequence, untreated primary tumors which express this mutation are associated with aggressive clinical features, such as larger tumor size and lymph node-positive status [29] . The K303R mutation also exhibits increased binding to growth factor receptors, such as HER2 and insulin-like growth factor receptor (IGF1R), which further enhances downstream signaling molecules, such as the p85a regulatory subunit of PI3K [32, 38, 39] , Activation of IGF1R in primary tumors has also been reported [28] , highlighting that evolving breast tumors may use multiple, parallel, or complementary mechanisms of resistance to survive (e.g., mutation of ERa and activation of IGF1R) coordinately providing a selective growth advantage during treatment. Overexpression of the K303R mutation also confers hypersensitivity to estrogen growth stimulation [38, 40] , again a selective growth advantage compared to wild-type receptor in women with low circulating levels of estrogen. In preclinical models, cells expressing the mutation also exhibit enhanced communication with cytokines, such as leptin, leading to increased invasive growth [41] . Importantly, the mutant receptor directs enhanced bidirectional cross-talk between ER and growth factor receptors such as HER2 and IGF1R [32, 39] , which again together could coordinately play an important role in resistance to hormonal agents.
AIs are the most effective hormonal treatment of ERapositive breast cancers, and are currently sequenced with Tam during the management of patients, with recent data demonstrating that extended durations of hormonal therapy may be needed for effective long-term control of late recurrence [42] . To explore the role of the K303R mutation and subsequent activation at ERa S305 in AI resistance (AI R ), a preclinical model was developed via stable transfection of an aromatase expression vector in K303R-overexpressing breast cancer cells [43] . The aromatase substrate androstenedione (AD) increased growth via its conversion to estrogen by aromatase in this model, and the AI anastrozole (Ana) decreased AD-stimulated growth of wild-type ERa-expressing cells, whereas mutant-expressing cells were resistant to the inhibitory effect of Ana on growth. Resistance occurred through constitutive activation of the PI3K/Akt pro-survival signaling pathway to which the mutant cells had become addicted for maintenance of growth [38] , and specific IGFR1R and Akt inhibitors restored AI sensitivity in mutant-expressing cells. The clinical implications of this translational research are that mutant-expressing cells may escape from growth inhibition when treated with AIs, and that the development of treatment strategies utilizing specific biologic inhibitors may be required to extend the duration of sensitivity to estrogen deprivation, or to reverse resistance at its emergence. Thus, the growth addiction of the K303R ERa mutation might also prove to be its clinical ''Achilles heel.'' Importantly, inhibiting S305 phosphorylation with a blocking peptide also inhibited IGF1R/IRS-1/Akt signaling, and restored AI sensitivity. It was hypothesized that the K303R mutation and the S305 ERa residue are determinants of AI response, and that blockade of S305 phosphorylation represents a new therapeutic strategy for treating tumors resistant to hormone therapy. In summary, extensive preclinical data suggest that the K303R ERa mutation might be a new predictive marker to identify patients who will develop resistance to hormonal therapy. We encourage investigators to examine primary and metastatic tumor samples using primer-extension sequencing methods (such as the SnapShot TM and Sequenom TM technologies) capable of detecting this important ERa mutation site, so that it's full clinical significance can be realized.
Mutational hot spot in ERa: leucine (L) 536, tyrosine (Y) 537, and aspartate (D) 538
The Y537 to asparagine (N) mutation was discovered in 1997 occurring in 1/30 metastatic breast tumors [44] . This mutation eliminates a tyrosine residue that is an important c-Src phosphorylation site with roles in regulating ligand binding, dimerization, and transcriptional activity of ERa [45, 46] , and replaces it with a residue which induced a conformational change which mimics hormone binding. The Y537N ERa mutation exhibited highly elevated ligand independent, constitutive transcriptional activity; thus, cells expressing the mutant were resistant to tamoxifen treatment, and were only partially inhibited by treatment with the pure steroidal antiestrogen fulvestrant. It was postulated at that time that a mutation at this site induced a conformational change in ERa allowing escape from normal phosphorylation-mediated regulatory controls, providing cells with a selective oncogenic advantage during tumor progression, especially during treatment with hormonal therapies [44] . Similarly, Dr. Benita Katzenellenbogen's group examining in vitro-derived mutations surrounding the Y537 site hypothesized that these mutations mimic many of the changes in ER properties which are normally under estrogen control [45] . Subsequently, Dr. Murphy and colleagues reported that phosphorylation at Y537 ERa was associated with poor clinical outcome in breast cancer patients treated with tamoxifen [47] . A recent study has demonstrated that ERa phosphorylation at Y537 by Src can trigger promoter occupancy and specific target gene expression [48] , thus this site may be a critical regulatory site.
Recently several reports have confirmed the earlier results on Y537, extending the number of different mutations at the Y537 ERa site in metastatic breast tumors, and have demonstrated that this region corresponds to an ERa mutational hot spot region with somatic mutations in the surrounding residues L536 and D538. Undoubtedly realization of these important results can be attributed to the power of deep Next Generation sequencing and genomic interrogation of metastatic tumors, an area which has been underexplored until recently. Dr. Ellis' group was the first to report that 3/15 metastatic tumor samples maintained as patient-derived xenografts in mice harbored an Y537S mutation [49] . Like the Y537N mutation, the Y537S mutation exhibited high constitutive ER transcriptional activity and high levels of the estrogen-responsive progesterone receptor, and was only partially responsive to growth inhibition with fulvestrant treatment. These investigators also speculated that the mutation could arise as an adaption to endocrine therapy, potentially providing a mechanism of aromatase inhibitor resistance. Further strong support for the important role of this ER region comes from two reports just published [50, 51] . In the study from Dr. Chinnaiyan's group, 5/11 metastatic tumors contained mutations in this region (L536G, Y537S, Y537C, Y537N, and D538G) [50] . In contrast to previous studies finding relative resistance to antiestrogens, these authors report that the ER transcriptional activity of all five mutations was inhibited by tamoxifen and fulvestrant. The reason for the differences between their results and others is not known; however, growth response assays were not presented in this study. Mutations in this region appear to be frequent with 9/36 metastatic tumors sequenced by Toy et al. [51] harboring nonsynonymous substitutions at this hotspot. Molecular dynamic simulations suggest that the structures of the Y537S and D538G mutants involve hydrogen bonding of the mutant favoring the agonist conformation of the receptor [51] . This finding supports molecular structure-function work by earlier pioneering investigators [45, 46] . Importantly, Toy et al. [51] report that hormone-independent growth and activity were observed in cells expressing mutations within this positional hotspot, and that mutant-expressing cell growth was only partially responsive to antiestrogens. In summary, it is clear that mutations in this region might be particularly frequent in metastatic breast tumors, and warrant exploration for their utility as predictive markers in metastatic patients, especially those on aromatase inhibitor regimens. Figure 3 depicts the genomic location of all reported ERa mutations to date in primary and metastatic breast tumors. [22, 26-30, 44, 49-51, 53, 55, 61-66] The 303 and 536-538 ERa receptor residues are undoubtedly two functionally important sites for somatic gain-offunction mutations in primary and metastatic tumors, respectively. Although currently infrequent other mutations have been reported, for instance at the E380 site within the ligand-binding domain [50] , and the S118 residue which is a MAPK phosphorylation site that can significantly alter hormone binding and function [52] [53] [54] . The D538G mutation is significant in that it was identified in five liver metastases, but not in the matched primary tumors, from patients who had failed multiple hormonal therapies, [55] . Modeling of the D538G substitution leads to a conformational change in the ligand-binding domain which mimics the conformation of activated ligand-bound receptor, and alters the binding of tamoxifen [55] . Many of the other additional mutations shown in Fig. 3 have previously been reviewed [56] , and will not be detailed further herein. It is certainly easy to predict that further site-specific alterations in the ligand-binding domain will be identified once deep genomic sequencing is routinely employed to interrogate metastatic lesions where tumor evolution and the selective pressures of treatment could encourage subclonal expansion during metastatic dissemination.
Conclusions and clinical implications
Recent guidelines for the workup of metastatic breast cancer patients suggest that the first recurrence of disease should be biopsied [57] , but this is not always done for a number of practical or conservative clinical reasons. General clinical acceptance of the high probability of ERa mutations in tumors that will help inform treatment decisions should encourage the acquisition of biopsies from all metastatic patients when possible, especially those accessible tumors which grew while on hormonal therapies. Looking for ERa mutations in metastatic tumors can be likened to the mystery in Poe's ''Purloined Letter''-hidden in plain sight. It was predictable that such an important growth regulatory pathway like the ER transcriptional network in breast cancer would evolve and mutate to evade therapy. Thus, as originally proposed [1] , it is reasonable to assert that both the maintenance of ERa expression, and the evolution of biologic attributes which are advantageous for the complex process of invasion and metastasis, all which ERa gain-of-function mutations can affect, would prove to be important for the progression of ER-positive breast tumors. These data also suggest that ERa mutation analysis in metastatic tumors should become mainstream after appropriate prospective clinical studies confirming their utility, and that mutation analyses will then be used to make decisions on the hormonal treatment of patients with ER-positive recurrent breast cancers.
With the relative resistance of the reported mutations in metastatic disease to existing therapies, there is also an urgent need to search for better receptor antagonists. For instance, final results from the CONIRM trial demonstrated the therapeutic superiority of higher dose (500 mg) fulvestrant in postmenopausal women with locally advanced or metastatic ER-positive breast cancer that had recurred or progressed after prior hormone therapy [58] . It remains to be determined if tumors with specific ERa mutations will be responsive to higher doses of fulvestrant.
Phosphorylation is a critically important regulator of receptor function. We need new biologic approaches, such as stable peptide mimetics, to block the downstream effectors of mutant receptors. Such an approach was used to block the phosphorylation and cellular crosstalk of the K303R ERa mutant receptor with the growth factor receptor pathway in preclinical models [32, 39] , and similar strategies could be employed for the other receptor mutational hotspots such as the Y537 site [59] . From a therapeutic standpoint, knowing the mutational status of the Y537 hotspot might only be helpful in women who present with metastatic disease where traditional hormonal blockade with tamoxifen or aromatase inhibitors might not be most effective. However, in cells where resistance occurs due to expression of the K303R ERa mutation, hormone sensitivity can be restored by inhibitors which block mutant receptor crosstalk involving IGF1R and Akt signaling, suggesting that mutant-expressing cells may have become addicted to particular growth pathways. Thus, the K303R mutation is an actionable target with current therapeutic strategies. Determining whether the Y537 hotspot also has similar therapeutic vulnerability to biologic targeted therapies should be a translational research priority. Figure 4 summarizes the potential clinical implications of ERa mutation analysis in breast cancer. Primary tumors are treated with aromatase inhibitors, tamoxifen, or a serial combination. Both of these hormonal therapies are very effective in the adjuvant setting, with long durations of patient responses. Deep sequencing of primary tumors to detect subclonal populations expressing mutant receptors is probably clinically warranted to help appropriately guide adjuvant therapy. In addition, sequencing techniques which can detect the presence of the K303R ERa mutation in primary tumors, even though its absolute frequency has not been established as of yet, are needed to help guide the treatment of patients with this mutation. Emerging technologies such as sequencing of circulating tumor cell DNA might afford opportunities to monitor the progression of subclonal populations expressing relevant mutant receptors [60] . Upon first recurrence, genomic and proteomic analysis could identify both mutant cell populations and downstream effector pathways of mutant transcriptional activity, so that specific biologic targeting strategies could be offered along with switching of hormonal therapies to agents such as high dose fulvestrant. These proposed clinical approaches are feasible and could encompass a more rational precision paradigm for the future benefit of women with ER-positive breast cancer.
Finally, we must stress that ERa mutations might also be important early during the evolution of premalignant lesions to primary cancer. The K303R ERa mutation was originally discovered in premalignant atypical ductal hyperplasias with an even higher frequency detected in invasive breast tumors [26] . An ERa mutation which confers a proliferative advantage, such as hypersensitivity to estrogen, could provide a favorable cellular environment to accelerate the accumulation of additional genetic events important for tumor progression [26] . Indeed, Dr. Conway's group has also reported that the K303R ERa mutation was a risk factor for breast cancer in women with a familial history of breast cancer [28] . The association of the K303R ERa mutation with familial breast cancer risk has also been reported in Asian-Caucasian (Iranian) breast cancer patients; the frequency of the mutation in this cohort was 10 % [30] . The use of deep sequencing techniques or single cell sequencing of DNA from heterogeneous lesions might afford a better understanding of not only the frequency of specific ERa mutations, but also the life history and evolution of these mutations during breast tumor treatment and progression.
